$0.78
+0.04 (+5.61%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CELU is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
17 interventional · 4 with posted results
Held by 2 tracked-famous managers (CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 7.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaNCT05207722Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: for business reasons | Biological: CYNK-101 · Drug: Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna | Metastatic HER2 Positive Gastroesophageal Junction Cancer | 1 | 2024-02-15actual | 2024-12-12 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaNCT04309084Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Unknown status | Biological: CYNK-001 | Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Hemostatic Disorder, Vascular Diseases, Cardiovascular Diseases, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases, Antineoplastic Agents, Analgesics, Non-Narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs | 29 | 2023-01-31actual | 2023-02-16 |
| Natural Killer Cell (CYNK-001) Infusions in Adults with AMLNCT04310592Number of Participants who experience a Dose-limiting Toxicity (DLT) in MRD positive AML patientsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Biological: CYNK-001 | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML | 27 | 2023-01-20actual | 2024-12-12 |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeNCT05218408Phase I-Number of patients experience Dose limiting toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: No participants were enrolled. Study was withdrawn prior to treatment initiation. | Biological: CYNK-001 systemic and Intra cavity administration | Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma, Glioblastoma Multiforme | 0 | 2021-10-23actual | 2026-06-08 |
| Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19NCT04365101results2026-06-01Phase 1: Frequency and Severity of Adverse Events (AE)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: Lack of enrollment due to COVID treatment options availability. | Biological: CYNK-001 | Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic | 7 | 2021-08-30actual | 2026-06-26 |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBMNCT04489420Number of Participants who experienced a Dose-Limiting Toxicity (DLT)Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision. | Biological: CYNK001-IV, CYNK001-IT | Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents | 3 | 2021-08-10actual | 2022-08-10 |
| A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)NCT02955550Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Completed | Drug: rhIL-2 · Biological: PNK-007 | Multiple Myeloma | 15 | 2018-07-10actual | 2020-07-22 |
| Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.NCT02264288results2026-06-12Percentage of Subjects With Complete Wound Closure of the Index Ulcer Within 3 MonthsRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early due to a business decision. | Biological: PDA-002 · Other: Placebo | Peripheral Arterial Disease, Diabetic Foot | 159 | 2018-02-27actual | 2026-06-12 |
| A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)NCT02781467Dose-Limiting Toxicity (DLT)Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business Decision | Biological: PNK-007 · Drug: Cyclophosphamide, Fludarabine, Human recombinant Interleukin-2 (rhIL-2) | Leukemia, Myeloid, Acute | 10 | 2017-12-07actual | 2020-07-22 |
| A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral NeuropathyNCT02552277Percent change in the epidermal nerve fiber density (ENFD) at 6 months, compared to baselineRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: PDA-002 · Drug: Placebo | Diabetic Nephropathies, Peripheral Nervous System Diseases | 26 | 2017-03-07actual | 2022-02-02 |
| Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot UlcersNCT01859117results2026-06-04Dose Limiting Toxicity (DLTs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Biological: PDA-002 | Peripheral Arterial Disease, Diabetic Foot Ulcer | 15 | 2016-10-01actual | 2026-06-04 |
| Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial DiseaseNCT02460081Ankle-brachial Index (ABI)Randomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: The study was withdrawn prior to enrollment. Four subjects were screened but did not meet eligibility criteria; therefore, no subjects were enrolled. The study was not pursued further for administrative reasons. | Drug: PDA-002, Placebo | Diabetic Foot, Peripheral Arterial Disease | 0 | Jan 2016actual | 2026-04-29 |
| A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's DiseaseNCT01769755Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Biological: PDA001 · Drug: Vehicle Controlled Placebo | Crohns Disease | 14 | Nov 2014actual | 2018-03-01 |
| Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary SarcoidosisNCT01440192Evaluate pulmonary artery pressure during infusionNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study Terminated by Sponsor | Biological: PDA001 (cenplacel-L) | Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis | 4 | Feb 2014actual | 2018-03-01 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic StrokeNCT01310114Safety (Type, frequency, severity and potential relationship to study drug of adverse events)Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study terminated by sponsor | Biological: Human Placenta-Derived Cells PDA001- (cenplacel-L) · Drug: Placebo | Stroke, Acute, Middle Cerebral Artery Stroke, Posterior Cerebral Artery Stroke | 44 | Mar 2013actual | 2018-03-01 |
| PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's DiseaseNCT01155362results2026-07-07Percentage of Subjects With Clinical Response Based on Crohn's Disease Activity Index (CDAI) at Both Week 4 and Week 6Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Biological: Human Placenta-Derived Cells PDA001 Intravenous Infusion · Drug: Vehicle Control | Crohn's Disease | 50 | Feb 2012actual | 2026-07-07 |
| Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid ArthritisNCT01261403Number/Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response within 12 weeks following the initial dose of study drugRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Enrollment terminated pending additional Phase 1 data | Biological: PDA001 · Drug: Vehicle Controlled Placebo | Rheumatoid Arthritis | 26 | Feb 2012actual | 2020-07-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19